Cambrex Corporation operates in the Pharmaceutical preparations sector. Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to pharmaceutical companies and generic drug companies. Its business includes primarily the development and manufacture of pharmaceutical ingredients derived from organic chemistry. Cambrex's products include active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Services include custom development and current Good Manufacturing Practices (cGMP) manufacturing services. In November 2010, the Company acquired a 51% interest in Zenara Pharma, an India-based pharmaceutical company focused on the formulation of final dosage form products. In March 2010, the Company completed the acquisition of IEP GmbH (IEP), a company in Wiesbaden, Germany, which is engaged in the field of industrial biocatalysis. In our complete report available for purchase the company is compared to: American Vanguard Corporation, Balchem Corporation and Sucampo Pharmaceuticals, Inc..